Immune-mediated anaemia is a collective term describing the occurrence of anaemia due to an immune dysfunction, leading directly or indirectly to the destruction of red blood cells. In recent years, as knowledge of the immune system has progressed, these disorders have also become better understood and their management improved. Monoclonal antibodies have emerged as a powerful tool in the treatment of many different disorders, including both haematological and non-haematological disorders. Most experience has been obtained with the use of rituximab, a chimeric mouse/human anti-CD20 monoclonal antibody, showing high overall response rates with a relatively safe toxicity profile.
Evidence on the use of rituximab in AIHA is mainly based on retrospective case reports and case series, with only a few prospective trials. Nevertheless, based on these rather small series, information on about 300 patients has been reported, leading to overall response rates of more than 60%, with complete response rates exceeding 25%. 4, 12 However, these numbers need to be interpreted with caution, as patients not responding are unlikely to be reported in case reports and smaller series.
Although patients experiencing warm AIHA can often be treated successfully with corticosteroids and/or splenectomy, these treatment options are very disappointing in primary cold agglutinin disease (CAD). CAD has traditionally been treated upfront with cytotoxic therapy, displaying a substantial toxicity profile. Recent findings using rituximab in CAD showing overall response rates of 50-65% in retrospective and prospective uncontrolled trials have led to the general assumption that rituximab, either in monotherapy or combined with alkylating agents or purine analogues, should be used as a first-line treatment in CAD. [12] [13] [14] [15] AIHA is a well-known complication of lymphoproliferative disorders, especially chronic lymphocytic leukaemia (CLL). Based on its potent activity in these disorders, either in monotherapy or combined with chemotherapeutic agents, rituximab has been used in lymphoproliferative-disorder-associated AIHA. The combined immunochemotherapeutic regimen rituximab-cyclophosphamide-dexamethasone in particular seems to be associated with very high and durable responses in CLL-associated AIHA.
16,17
Whether rituximab can be used as a splenectomy-sparing second-line therapy in warm AIHA has yet not been studied properly. However, in ITP -which can be considered the platelet analogue of AIHArituximab is now considered a valuable alternative in patients not fit enough to undergo or refusing splenectomy. 
Platelet (THR) and red blood cell (RBC) antigens are cleaved by antigen-presenting cells (APCs) and presented as peptides on their surface via major histocompatibility complex (MHC) class II molecules. This complex is recognised by the T-cell receptor (TCR) of the CD4-positive T-helper (Th) cell. Additional co-stimulatory signals are provided by CD80-CD28 and CD40-CD154 interactions. The activated Th cells produce activating cytokines (such as interleukin-2 and interferon-gamma), which cause activation and differentiation of B cells, leading to auto-antibody production. Auto-antigens on the surface of platelets and RBCs are recognised by the Fab part of the auto-antibodies. Auto-antibody-coated platelets and

Rituximab in Thrombotic Microangiopathy
TMA is a life-threatening disorder characterised by Coombs-negative micro-angiopathic haemolytic anaemia, thrombocytopenia and formation of microthrombi in different organs, especially the kidneys, heart and central nervous system. Although anaemia in TMA is caused by mechanical fragmentation of red blood cells, TMA is immunemediated in a substantial proportion of patients.
25,26
The term TMA comprises different entities, including thrombocytopenic thrombotic purpura (TTP) and haemolytic uremic syndrome (HUS). Broadly, TMA can be divided into three different categories:
• a disintegrin and metalloproteinase with thrombospondin type 1, 13, the member (ADAMTS13)-deficiency TTP (congenital or acquired);
• HUS (typical and atypical); and
• secondary TMA (see Table 1 ).
27,28
Acquired ADAMTS13-deficiency TTP is a typical autoimmune disorder caused by the formation of auto-antibodies against ADAMTS13. This enzyme is responsible for cleavage of ultralarge von Willebrand factor (ULvWF) multimers. Due to these antibodies, ULvWF multimers are not or are insufficiently cleaved in patients with TTP, leading to profound platelet consumption, fragmentation of red blood cells and occlusion of small blood vessels in different organs (see Figure 2 ).
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Although initial treatment of TMA consists of urgent daily therapeutic plasma exchange, 30 treatment with rituximab is a promising approach in immune-mediated TMA, both as an adjunctive treatment to therapeutic plasma exchange and in case of relapse. 4 Currently, the experience with rituximab is limited to a few smaller case series and case reports on relapsing and refractory cases of TTP. Taken together, rituximab therapy seems to provide the most benefit in patients with severe ADAMTS13 deficiency due to ADAMTS13 auto-antibodies, which seems to be associated with a significantly higher relapse rate compared with patients with non-severely deficient ADAMTS13 activity levels. 31 Currently, more than 100 patients have been reported, with severe ADAMTS13 deficiency being documented in about 80% of these patients. In most of these cases, rituximab was used at the The Use of Rituximab in Immune-mediated Anaemia 
